{"result": {"id": "9e6cf4e5-43ee-4c98-9f20-814707d26ce9", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>THIAZIDE DIURETICS<|>ORGANIZATION<|>A class of antihypertensive drugs recommended by the 2018 Chinese Hypertension Guidelines for initial and maintenance therapy\")\n##\n(\"entity\"<|>BETA-BLOCKERS<|>ORGANIZATION<|>A class of antihypertensive drugs that block the effects of adrenaline, reducing heart rate and blood pressure\")\n##\n(\"entity\"<|>SPC<|>ORGANIZATION<|>Single Pill Combinations of antihypertensive drugs recommended by the 2018 Chinese Hypertension Guidelines\")\n##\n(\"entity\"<|>EAST ASIA<|>GEO<|>Region where dihydropyridine CCBs are particularly widely used for hypertension treatment\")\n##\n(\"relationship\"<|>THIAZIDE DIURETICS<|>2018 CHINESE HYPERTENSION GUIDELINES<|>Thiazide diuretics are one of the recommended drug classes in the 2018 guidelines<|>7)\n##\n(\"relationship\"<|>BETA-BLOCKERS<|>2018 CHINESE HYPERTENSION GUIDELINES<|>Beta-blockers are one of the recommended drug classes in the 2018 guidelines despite some limitations in evidence<|>6)\n##\n(\"relationship\"<|>SPC<|>2018 CHINESE HYPERTENSION GUIDELINES<|>Single Pill Combinations are recommended as initial and maintenance therapy in the 2018 guidelines<|>8)\n##\n(\"relationship\"<|>CCB<|>EAST ASIA<|>Dihydropyridine CCBs are particularly widely used in East Asia for hypertension treatment<|>7)\n##\n(\"relationship\"<|>THIAZIDE DIURETICS<|>CCB<|>Both are recommended first-line antihypertensive drug classes in the guidelines<|>5)\n##\n(\"relationship\"<|>THIAZIDE DIURETICS<|>ACEI<|>Both are recommended first-line antihypertensive drug classes in the guidelines<|>5)\n##\n(\"relationship\"<|>THIAZIDE DIURETICS<|>ARB<|>Both are recommended first-line antihypertensive drug classes in the guidelines<|>5)\n##\n(\"relationship\"<|>BETA-BLOCKERS<|>CCB<|>Both are antihypertensive drug classes though with different mechanisms of action<|>4)\n##\n(\"relationship\"<|>BETA-BLOCKERS<|>ACEI<|>Both are antihypertensive drug classes though with different mechanisms of action<|>4)\n##\n(\"relationship\"<|>BETA-BLOCKERS<|>ARB<|>Both are antihypertensive drug classes though with different mechanisms of action<|>4)\n##\n(\"relationship\"<|>SPC<|>CCB<|>SPCs may contain CCBs as part of their combination therapy<|>6)\n##\n(\"relationship\"<|>SPC<|>ACEI<|>SPCs may contain ACEIs as part of their combination therapy<|>6)\n##\n(\"relationship\"<|>SPC<|>ARB<|>SPCs may contain ARBs as part of their combination therapy<|>6)\n##\n(\"relationship\"<|>SPC<|>THIAZIDE DIURETICS<|>SPCs may contain thiazide diuretics as part of their combination therapy<|>6)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558640, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 750, "prompt_tokens": 3123, "total_tokens": 3873, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3072}, "prompt_cache_hit_tokens": 3072, "prompt_cache_miss_tokens": 51}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 。\n　　　(5) 服药时间 :一般高血压患者通常应在早晨服用  降压 药 。早 上 与 晚 上 服 药 降 压 治 疗 ( treatment in morning versusevening,TIME)研究结果显示[237]  ,与  早上服药相比 ,晚上服用降压药并不能带来更多心血  管获益 。除非明确需要控制夜间血压升高 ,不应常规  推荐睡前服用降压药[145] 。\n　　　(6)个体化治疗 :根据患者合并症的不同和药物疗 效及耐受性 , 以及患者个人意愿或长期承受能力 ,选择 适合患者个体的降压药。\n　5.2.2.3   降压药的分类   2018年版中国高血压防治 指南推荐的常用降压药包括 CCB、ACEI、ARB、噻嗪 类利尿剂和 β 受体阻滞剂 , 以及由上述药物组成的 SPC。本指南补充血管紧张素受体脑啡肽酶抑制剂 (angiotensin receptor-neprilysin inhibitor, ARNI) 为 新的一 类 常 用 降 压 药 。本 指 南 建 议 以 上 降 压 药 和 SPC均可作为初始和维持治疗的常用药物。\n　　　不同患者所存在的危险因素、靶器官损害以及合  并临床疾病并不相同 ,这些临床情况可称为强适应证。 据此优先选择某类降压药 ,是高血压分层和精准化血  压管理的需求[238-239] 。不同种类、同一种类的不同药物 ,  降压作用的持久性和服药中断率可能有所差异[133] 。\n　　　降压治疗的获益主要源于血压的降低 。有的荟萃 分析报告了一些药物之间对特定心血管事件预防作用 有差异[133,135]  ,然而 , 总的来说 ,基于初始治疗的几类 常用降压药带来的获益都是相似的 。虽然部分 β受体 阻滞剂尚缺乏某些随机对照试验证据 ,但整个高血压 进展过程中都伴随着交感神经系统的过度激活 ,且伴 有多种疾病的高血压患者可从 β受体阻滞剂治疗中 受益[240] 。\n\n\n　　我国常用降压药和 SPC及其适应证和禁忌证介 绍见表 15~17。\n　　　(1) CCB: CCB主要通过阻断血管平滑肌细胞上 的钙离子通道发挥扩张血管降低血压的作用 。可大致 分为两类 :二氢吡啶类 CCB和非二氢吡啶类 CCB。在 东亚地区 ,二氢吡啶类 CCB因其降压效果(包括降低 夜间收缩压) 突出 ,是应用最为广泛的降压药[241] 。长 效二氢吡啶类 CCB能够改善夜间、清晨血压控制和 BPV[242-243] 。\n　　我国既往完成的较大样本的降压治疗临床试验多 以二氢吡啶类 CCB为研究用药 ,并证实以二氢吡啶类 CCB为基础的降压治疗方案\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>TIME STUDY<|>EVENT<|>The TIME study compared the effects of taking antihypertensive medication in the morning versus the evening, finding no additional cardiovascular benefits from evening dosing)\n##\n(\"entity\"<|>2018 CHINESE HYPERTENSION GUIDELINES<|>EVENT<|>The 2018 Chinese Hypertension Guidelines recommended common antihypertensive drugs including CCB, ACEI, ARB, thiazide diuretics, and beta-blockers, and introduced ARNI as a new class of antihypertensive drugs)\n##\n(\"entity\"<|>CCB<|>ORGANIZATION<|>Calcium Channel Blockers are a class of antihypertensive drugs that work by blocking calcium channels in vascular smooth muscle cells, widely used in East Asia for their effectiveness in lowering blood pressure)\n##\n(\"entity\"<|>ACEI<|>ORGANIZATION<|>Angiotensin-Converting Enzyme Inhibitors are a class of antihypertensive drugs that help relax blood vessels by preventing the formation of angiotensin II)\n##\n(\"entity\"<|>ARB<|>ORGANIZATION<|>Angiotensin II Receptor Blockers are a class of antihypertensive drugs that block the effects of angiotensin II, helping to relax blood vessels)\n##\n(\"entity\"<|>ARNI<|>ORGANIZATION<|>Angiotensin Receptor-Neprilysin Inhibitors are a newer class of antihypertensive drugs recommended by the 2018 Chinese Hypertension Guidelines)\n##\n(\"relationship\"<|>TIME STUDY<|>2018 CHINESE HYPERTENSION GUIDELINES<|>The TIME study's findings influenced the recommendations in the 2018 Chinese Hypertension Guidelines regarding the timing of antihypertensive medication<|>6)\n##\n(\"relationship\"<|>CCB<|>ACEI<|>Both CCB and ACEI are classes of antihypertensive drugs recommended by the 2018 Chinese Hypertension Guidelines<|>5)\n##\n(\"relationship\"<|>CCB<|>ARB<|>Both CCB and ARB are classes of antihypertensive drugs recommended by the 2018 Chinese Hypertension Guidelines<|>5)\n##\n(\"relationship\"<|>CCB<|>ARNI<|>CCB is a traditional class of antihypertensive drugs, while ARNI is a newer class introduced in the 2018 Chinese Hypertension Guidelines<|>4)\n##\n(\"relationship\"<|>ACEI<|>ARB<|>Both ACEI and ARB are classes of antihypertensive drugs that target the angiotensin system<|>7)\n##\n(\"relationship\"<|>ACEI<|>ARNI<|>ACEI is a traditional class of antihypertensive drugs, while ARNI is a newer class that includes neprilysin inhibition<|>4)\n##\n(\"relationship\"<|>ARB<|>ARNI<|>ARNI includes an ARB component, making it related to the traditional ARB class of antihypertensive drugs<|>6)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_184249fb8fe25b59ba8f04d87c03817bc24c725e61eba87a836879d2ec500828_v2"}